The overall goals of the Montefiore Medical Center (MMC) minority-based NCORP community site are to advance the diagnosis, prevention, and management of early and advanced cancer by participating in the NCORP as a minority/underserved community site. This will be accomplished by leveraging the partnership between MMC, which brings strengths in integrated patient care and innovative health care delivery systems serving a largely minority population, and the Albert Einstein College of Medicine and Cancer Center (Einstein), which brings strength in cancer clinical research through its NCI-designated cancer center. The MMC-Einstein program also brings critical leadership to the ECOG-ACRIN Research Group and NRG NCORP research bases, including leadership roles at the level of the group chair's office, scientific committee chair (or co-chair) and protocol chair (or co-chair). Our plans build upon our long-standing involvement in all aspects of cancer research as a main member of ECOG for nearly 40 years and an NCI designated cancer center for 43 years, and a strong history of minority accrual to cancer treatment trials (about two-thirds of all patients). MMC serves the Bronx, an urban community of 1.4 million residents, of whom 89% are minorities and 29% live below the federal poverty level. As an NCORP site, we will combine our strengths in cancer therapeutics with broader institutional capacity in prevention, screening and cancer care delivery, including: a newly established Community Oncology section in our cancer center; an extensive practice-based research network in primary care; our affiliation with safety-net public hospitals in the Bronx; an our innovative models of integration care management, delivery and financing, including our CMS-supported Pioneer Accountable Care Organization. Our site is poised to make a strong contribution to the national mission and goals of NCORP. The MMC-Einstein NCORP program is led by individuals with experience and federal funding in cancer therapeutics and cancer control (Dr. Joseph Sparano), cancer prevention (Dr. Mark Einstein), and cancer control and delivery (Dr. Bruce Rapkin), and supported by a cadre of other funded investigators.

Public Health Relevance

The MMC-Einstein will advance the diagnosis, prevention, and management of early and advanced cancer in minority populations by its participation in trials sponsored by NCRORP research bases, and by providing key scientific and administrative to the ECOG-ACRIN and NRG research bases.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Russo, Sandra
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Montefiore Medical Center (Bronx, NY)
New York
United States
Zip Code
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Marcelletti, John F; Sikic, Branimir I; Cripe, Larry D et al. (2018) Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. Cytometry B Clin Cytom :
Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
In, Haejin; Langdon-Embry, Marisa; Gordon, Lauren et al. (2018) Can a gastric cancer risk survey identify high-risk patients for endoscopic screening? A pilot study. J Surg Res 227:246-256
Rakovitch, E; Gray, R; Baehner, F L et al. (2018) Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat 169:359-369
Morgans, Alicia K; Chen, Yu-Hui; Sweeney, Christopher J et al. (2018) Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095
Sparano, Joseph A (2018) Prognostic gene expression assays in breast cancer: are two better than one? NPJ Breast Cancer 4:11
Rapkin, Bruce D; Weiss, Elisa; Lounsbury, David et al. (2017) Reducing Disparities in Cancer Screening and Prevention through Community-Based Participatory Research Partnerships with Local Libraries: A Comprehensive Dynamic Trial. Am J Community Psychol 60:145-159
Smith, M R; Hong, F; Li, H et al. (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31:517-519

Showing the most recent 10 out of 35 publications